Table 3 Select phase III trials of first, second, and third generation trials
From: Progress in adjuvant chemotherapy for breast cancer: an overview
Generation | Comparison (Reference) | Nodal status | Number of patients | Median follow-up (years) | Hazard ratio for disease-free survival | Hazard ratio for overall survival |
|---|---|---|---|---|---|---|
First | Positive | 386 | 28.5 | 0.71 (P = 0.005) | 0.79 (P = 0.04) | |
|  | CMF + Tam vs Tam (B20) [26] | Negative | 2306 | 5 | 0.65 (P = 0.001) | 0.64 (P = 0.03) |
|  | Positive | 2194 | 3 | P = 0.5* | P = 0.8* | |
|  | AC vs CMF (B23) [74] | Negative | 2008 | 5 | P = 0.9* | P = 0.4* |
|  | FEC50 + Tam vs Tam [76] | Positive | 457 | 9.4 | 0.46 (P = 0.0008) | 0.65 (P = 0.07) |
Second | FEC100 vs FEC50 [78] | Positive | 546 | 5.6 | 0.63 (P = 0.02) | 0.45 (P = 0.005) |
|  | ACx4-Tx4 vs ACx4 (C9344) [82] | Positive | 3121 | 5.8 | 0.83 (P = 0.002) | 0.82 (P = 0.006) |
|  | ACx4-Tx4 vs ACx4 (B28) [83] | Positive | 3060 | 5.4 | 0.83 (P = 0.006) | 0.93 (P = 0.46) |
|  | DCx4 vs ACx4 [85] | 0–3 Positive | 1016 | 7 | 0.74 (P = 0.033) | 0.69 (P = 0.032) |
| Â | Ex4-CMFx4 vs CMFx6/CMFx8 [84] | Positive Negative | 2391 | 4 | 0.69 (P <0.001) | 0.67 (P <0.001) |
Third | Positive | 1491 | 10.3 | 0.80 (P = 0.004) | 0.74 (P = 0.002) | |
|  | DAC vs FAC [91] | Negative | 1060 | 6.4 | 0.68 (P = 0.01) | 0.76 (P = 0.29) |
|  | Positive | 1099 | 7.8 | 0.85 (P = 0.036) | 0.75 (P = 0.007) | |
|  | FEC-weekly T vs FEC [95] | Positive | 1246 | 5.5 | 0.77 (P = 0.022) | 0.78 (P = 0.11) |
|  | FAC-weekly T vs FAC [113] | Negative | 1925 | 5.3 | 0.73 (P = 0.04) | 0.79 (P = 0.31) |
|  | Positive | 2005 | 5.8 | 0.80 (P = 0.01) | 0.85 (P = 0.04) | |
|  | Positive | 4954 | 12.1 | 0.84 (P = 0.011) | 0.87 (P = 0.09) | |
AC-T vs AC-D | 0.79 (P = 0.001 | 0.86 (P = 0.054) | ||||
|  | AC-D vs DAC [103] | Positive | 5351 | 6.1 | 0.83 (P = 0.01) | 0.86 (P = 0.09) |
AC-D vs AD | 0.80 (P = 0.001) | 0.83 (P = 0.03) |